Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker Study of Sunitinib plus Docetaxel in Hormone-Refractory Prostate Cancer
2007-003705-27Phase 2Completed
- Sponsor
- University Hospital Vienna
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of sunitinib in castration-resistant prostate cancer (CRPC) (2 arms), sponsored by University Hospital Vienna. Primary endpoint: Primary endpoint: reduction of circulating endothelial cells (CEC) and circulating endothelial progenitor cells (CEP). Started Oct 2007; status: completed.
02
Drugs
sunitinib
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on 2007-003705-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003705-27.